sur SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech Releases H1 2025 Financial Report
Sartorius Stedim Biotech SA has announced the availability of its report on the first half of 2025 financial results. The document can be accessed through their investor relations webpage. It provides insights into the business development from January to June 2025, alongside forecasts for the full year.
The report includes consolidated financial statements for the period ending June 30, 2025. Sartorius Stedim Biotech, headquartered in Aubagne, France, is a significant player in the biopharmaceutical sector. The company supports the manufacturing of biotech drugs, including cell and gene therapies. In 2024, it achieved sales revenue of approximately 2.8 billion euros and employs over 9,900 people worldwide.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de SARTORIUS STED BIO